<DOC>
	<DOC>NCT02509026</DOC>
	<brief_summary>The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.</brief_summary>
	<brief_title>Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA</brief_title>
	<detailed_description>This multcenter, open-label, three period study will evaluate withdrawal and retreatment of etanercept in subjects with nr-ax SpA who achieved adequate response following 24 weeks of treatment.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>diagnosis of axial SpA duration of symptoms &gt;3 months and &lt;5 years back pain with a less than favorable response to NSAIDs radiological sacroiliitis previous treatment with TNF inhibitor, biologic, immunosuppressive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-radiographic axial spondyloarthritis</keyword>
</DOC>